Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$10.51
$10.51
$3.75
$10.73
$769.27M-0.3219,508 shsN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$44.12
-3.5%
$37.08
$19.45
$53.27
$2.98B2.07629,929 shs3.80 million shs
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
$47.52
+0.5%
$41.82
$31.42
$58.26
$3.03B1.23385,623 shs923,933 shs
Metsera Inc. stock logo
MTSR
Metsera
$28.59
-0.4%
$26.70
$12.30
$37.99
$3.02BN/A1.02 million shs932,237 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00%0.00%0.00%0.00%0.00%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-3.48%-3.82%+53.19%+48.95%+47.61%
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
+0.49%+9.24%+24.50%+19.22%+18.24%
Metsera Inc. stock logo
MTSR
Metsera
-0.42%-3.41%+2.07%+2.11%+2,858,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2.8078 of 5 stars
4.51.00.00.03.01.70.0
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
2.2626 of 5 stars
3.51.00.00.03.32.50.0
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.00
N/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
3.00
Buy$59.6135.11% Upside
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
3.00
Buy$74.5056.78% Upside
Metsera Inc. stock logo
MTSR
Metsera
3.00
Buy$55.0092.37% Upside

Current Analyst Ratings Breakdown

Latest CNVY, MTSR, KYMR, and MLTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$56.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$59.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$57.00 ➝ $53.00
6/26/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $60.00
6/25/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$64.00
6/20/2025
Metsera Inc. stock logo
MTSR
Metsera
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00
6/10/2025
Metsera Inc. stock logo
MTSR
Metsera
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$56.00 ➝ $62.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$57.00 ➝ $64.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$38.00 ➝ $60.00
6/3/2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$49.00 ➝ $79.00
(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
$337.60M2.28$0.46 per share22.90$7.35 per share1.43
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$47.07M61.04N/AN/A$12.90 per share3.42
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/A$7.09 per shareN/A
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/A($2.46) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
-$9.98M-$0.10N/A25.63N/A-1.90%0.08%0.05%N/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$118.94M-$2.30N/AN/AN/AN/A-30.81%-28.40%8/6/2025 (Estimated)
Metsera Inc. stock logo
MTSR
Metsera
-$209.13MN/A0.00N/AN/AN/AN/AN/A

Latest CNVY, MTSR, KYMR, and MLTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
-$0.76-$0.63+$0.13-$0.63N/AN/A
5/12/2025Q1 2025
Metsera Inc. stock logo
MTSR
Metsera
N/A-$1.03N/A-$1.03N/AN/A
5/9/2025Q1 2025
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
N/AN/AN/AN/AN/A
Metsera Inc. stock logo
MTSR
Metsera
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
0.50
2.20
1.60
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
8.49
8.49
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
0.18
21.11
21.11
Metsera Inc. stock logo
MTSR
Metsera
N/A
6.55
6.55

Institutional Ownership

CompanyInstitutional Ownership
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
85.28%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
93.85%
Metsera Inc. stock logo
MTSR
Metsera
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Convey Health Solutions Holdings, Inc. stock logo
CNVY
Convey Health Solutions
3,80073.19 million68.66 millionNot Optionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
17065.12 million54.69 millionOptionable
MoonLake Immunotherapeutics stock logo
MLTX
MoonLake Immunotherapeutics
264.01 million56.32 millionOptionable
Metsera Inc. stock logo
MTSR
Metsera
81105.06 millionN/AN/A

Recent News About These Companies

Wells Fargo & Company Begins Coverage on Metsera (NASDAQ:MTSR)
Metsera (NASDAQ:MTSR) Shares Gap Up - Time to Buy?
Metsera (NASDAQ:MTSR) Shares Up 4.5% - Time to Buy?
Cantor Fitzgerald Estimates Metsera FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Convey Health Solutions stock logo

Convey Health Solutions NYSE:CNVY

Convey Health Solutions Holdings, Inc. provides technology enabled solutions and advisory services to assist its clients with workflows across product developments, sales, member experience, clinical management, core operations, and business intelligence and analytics. It operates through two segments, Technology Enabled Solutions and Advisory Services. The Technology Enabled Solutions segment offers technology solutions through web-based customizable application that is used to identify, track, and administer contractual services, or benefits provided under a client's plan to its Medicare and Medicaid beneficiaries. It also provides analytics over healthcare data to capture and assess gaps in risk documentation, quality, clinical care, and compliance. The company also offers health plan management, data analytics, supplemental benefit, advisory, and software services. The Advisory Services segment offers sales and marketing strategies, provider network strategies, compliance, star ratings, quality, clinical, pharmacy, analytics, and risk adjustment. It serves government sponsored, medicare advantage, medicare, as well as pharmacy benefits managers. The company was founded in 2001 and is headquartered in Fort Lauderdale, Florida. Convey Health Solutions Holdings, Inc. is a former subsidiary of TPG Cannes Aggregation, L.P.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$44.12 -1.59 (-3.48%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$44.12 0.00 (0.00%)
As of 06/27/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MoonLake Immunotherapeutics stock logo

MoonLake Immunotherapeutics NASDAQ:MLTX

$47.52 +0.23 (+0.49%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$45.88 -1.65 (-3.46%)
As of 06/27/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Metsera stock logo

Metsera NASDAQ:MTSR

$28.59 -0.12 (-0.42%)
As of 06/27/2025 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.